# Tranquilizer Drugs Market > Tranquilizer Drugs Market Research Report Information By Major Tranquilizers (Phenothiazine Derivatives, Butyrophenones, Thioxanthene Derivatives, and Others), By Minor Tranquilizers (Benzodiazepine Derivatives, Propanediol Dicarbamate Derivatives, Cyclopyrrolone Derivatives, and Others) and By Region (North America, Europe, Asia-Pacific, and Rest of the World) –Market Forecast Till 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 3.6% - **2024:** $ 2.26 Billion - **2025:** $ 2.34 Billion - **2035:** $ 3.33 Billion - **Key Players:** Pfizer (US), Bristol-Myers Squibb (US), Roche (CH), Sanofi (FR), AstraZeneca (GB), Novartis (CH), Eli Lilly (US), Teva Pharmaceutical Industries (IL), Mylan (US) **Report ID:** MRFR/Pharma/20120-HCR · **Pages:** 128 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** May 15, 2026 **URL:** https://www.marketresearchfuture.com/reports/tranquilizer-drugs-market-21718 --- ## Market Summary ## **Global Tranquilizer Drugs Market Overview** As per MRFR analysis, the Tranquilizer Drugs Market Size was estimated at 2.26 (USD Billion) in 2024. The Tranquilizer Drugs Market Industry is expected to grow from 2.34 (USD Billion) in 2025 to 3.22 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 3.60% during the forecast period (2025 - 2034). Increased spending on R&D to create new products and an increase in psychological problems are the key market drivers accelerating market expansion. Source: Primary Research, Secondary Research, MRFR Database and Analyst Review ## **Tranquilizer Drugs Market Trends** Market CAGR for tranquilizer drugs is being driven by the increase in the elderly population. Drugs known as tranquillizers are used to ease anxiety, quiet the mind, and promote a serene mindset without significantly hypnotizing or sedating the user. Tranquillizers are frequently utilized and play a significant role in psychological illnesses. Additionally, the market for sedative-hypnotic medications will grow as more initiatives by public and commercial organizations to raise awareness of various fungal illnesses are launched. Additionally, the market for sedative-hypnotic medications would grow due to people's high disposable money and inactive lifestyles. Along with this, the market's growth rate will be accelerated by the ageing population and an increase in thrombotic occurrences. Furthermore, the  market for sedative-hypnotic medications is projected to be driven by the exponential rise in incidence of chronic blood illnesses. The market is being driven by an increase in the prevalence of chronic disorders including cardiovascular diseases. One of the primary drivers of the growth rate of the world market for sedative-hypnotic medications is the increase in the prevalence of cardiovascular illnesses. Demand for sedative-hypnotic medications is expected to increase due to the growing number of geriatric people, who are more susceptible to cardiac disorders. In the upcoming years, it is expected that the proportion of people over 65 will double. Chronic illnesses are more prone to emerge in older people including cardiovascular disease, which may increase demand for sedative-hypnotic medications ly. Sedative-hypnotic medications, however, can have a number of adverse effects, such as fatigue, confusion, dizziness, and reduced coordination. These medicines can cause dependency, addiction, and withdrawal symptoms if used over an extended period of time or in excess. Sedative-hypnotic drug prescription rates and patient compliance may be affected by safety issues related to these medications. For instance, The WHO estimates that the world's elderly population, which was roughly 524 million in 2010, will grow to over 2 billion (22% of the world's population) by 2050. According to the National Alliance on Mental Illness, more than six million of the 35 million Americans 65 and older who live in the country suffer from depression. Thus, result in driving the Tranquilizer Drugs market revenue. ## **Tranquilizer Drugs Market Segment Insights** ### **Tranquilizer Drugs Major Tranquilizers Insights** The Tranquilizer Drugs market segmentation, based on Major Tranquilizers includes Phenothiazine Derivatives, Butyrophenones, Thioxanthene Derivatives, and Others. The butyrophenones segment dominated the market. Butyrophenones are advised for the management of tics and vocal utterances of Tourette's disorder in both children and adults, and they are utilized in psychotic diseases such as schizophrenia and mania. **Figure 1:  Tranquilizer Drugs Market, by Major Tranquilizers, 2022 & 2032 (USD Billion)** **** Source: Primary Research, Secondary Research, MRFR Database and Analyst Review ### **Tranquilizer Drugs Minor Tranquilizers Insights** The Tranquilizer Drugs market segmentation, based on Minor Tranquilizers, includes Benzodiazepine Derivatives, Propanediol Dicarbamate Derivatives, Cyclopyrrolone Derivatives, and Others. The benzodiazepine derivatives category generated the most income. The most often prescribed anxiolytic drugs are benzodiazepines. The GABA-A Receptor on the benzodiazepine receptor is where benzodiazepines bind. They improve how well GABA binds and works. Depression of the central nervous system occurs from this. ### **Tranquilizer Drugs Regional Insights** By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American Tranquilizer Drugs market area will dominate this market, because of the rising use of innovative technology and the rising need for treatments tailored to particular ailments. The increasing number of significant important players and rising healthcare costs will also accelerate the market's growth rate within the area. Further, the major countries studied in the market report are the US, German, France, the UK, Canada, Italy, Spain, India, Australia, South Korea, China, Japan, and Brazil. **Figure 2:  TRANQUILIZER DRUGS MARKET SHARE BY REGION 2022 (USD Billion)** **** Source: Primary Research, Secondary Research, MRFR Database and Analyst Review Europe Tranquilizer Drugs market represents the second-largest market share because of the region's increasing government activities and growing number of myocardial infarction instances. Further, the German Tranquilizer Drugs market held a dominant market share, and the UK Tranquilizer Drugs market was the European region's fastest-growing market. The Asia-Pacific Tranquilizer Drugs Market is expected to grow at the fastest CAGR from 2025 to 2034. This is due to the high prevalence of chronic diseases including AIDS, cancer, and other forms of mental illness in this area. Moreover, China’s Tranquilizer Drugs market held a dominant market share, and the Indian Tranquilizer Drugs market was the Asia-Pacific region's fastest-growing market. **Tranquilizer Drugs Key Market Players & Competitive Insights** Leading market players are putting a lot of money on R&D to broaden the range of their goods, which will help the market for tranquillizer drugs grow even more. Additionally, market participants are engaging in a range of strategic initiatives to increase their worldwide reach, with important market developments such as the introduction of new products, contracts, mergers and acquisitions, increased investments, and cooperation with other organizations. To grow and endure in an increasingly competitive and challenging market environment, Tranquilizer Drugs industry must provide reasonably priced goods. One of the main business strategies employed by manufacturers is to produce locally to reduce operational expenses in the  Tranquilizer Drugs industry to develop market sector and provide benefits to customers. In recent years, the Tranquilizer Drugs industry has provided the medical business with some of the most significant benefits. Major players in the Tranquilizer Drugs market, including AstraZeneca Plc., Eli Lilly and Company, GlaxoSmithKline plc, Merck & Co., Inc., Pfizer, Inc., Johnson & Johnson, and others, invest in operations for research and development in an effort to improve market demand. Anglo-Swedish multinational pharmaceutical and biotechnology firm AstraZeneca plc is headquartered in Cambridge, England at the Cambridge Biomedical Campus. Its product line includes treatments for serious illnesses in the cancer, cardiovascular, gastrointestinal, infectious, neurological, respiratory, and inflammatory fields. The majority of its R&D operations are based in Cambridge, England, Gothenburg, Sweden, and Gaithersburg, Maryland, in the United States. In 2021, Following the EMA's earlier clearance, the Swedish Medicines Agency, Läkemedelsverket, said that it would alter the vaccine's name to Vaxzevria, emphasizing that the vaccine's composition would remain the same. Eli Lilly and Company is an American pharmaceutical corporation with its main headquarters in Indianapolis, Indiana. About 125 nations sell its products. Colonel Eli Lilly, a pharmaceutical chemist and American Civil War veteran, started the business in 1876 and was the person who gave it its name. Merthiolate and penicillin production at Lilly reached a new peak during World War II. By the end of the war, Lilly had dried over two million pints of blood, or "about 20% of the total United States," working with the American Red Cross to process blood plasma during the conflict. In 2020, Lilly declared that its concoction was successful and that it has applied for an emergency use authorization (EUA) with the Food and Drug Administration. On the same day, Regeneron, a competitor, submitted a request for an EUA for a monoclonal antibody therapy. **Key Companies in the Tranquilizer Drugs market include** **Tranquilizer Drugs Industry Developments** **January 2021:** The Oxford-AstraZeneca vaccine has been given the go-ahead in India, the second-most populated nation on earth, opening the door for a widespread vaccination drive. The Serum Institute of India (SII), under the trade name COVISHIELD, was announced as the local manufacturer of the Oxford-AstraZeneca shot. **June 2021: **Bentracimab's European license from PhaseBio has been approved, according to Alfasigma. In earlier clinical trials, it was discovered that the new human monoclonal antibody fragment bentracimab could counteract Brilique's and Brilinta's antiplatelet effects. **May 2021**: Lilly's request for Tyvyt (sintilimab), in addition to Lilly's own Alimta (pemetrexed) and platinum chemotherapy, for newly discovered nonsquamous non-small cell lung cancer was approved by the FDA. ## **Tranquilizer Drugs Market Segmentation** ### **Tranquilizer Drugs Major Tranquilizers Outlook** ### **Tranquilizer Drugs Minor Tranquilizers Outlook** ### **Tranquilizer Drugs Regional Outlook** ## Market Drivers ### Growing Geriatric Population The increasing geriatric population is a significant factor driving the Tranquilizer Drugs Market. As individuals age, they often experience heightened levels of anxiety and other mental health issues, necessitating the use of tranquilizers for management. Data suggests that by 2030, the number of older adults is expected to reach 1.4 billion, creating a substantial market for tranquilizers tailored to this demographic. Additionally, the unique health considerations of older adults, such as polypharmacy and comorbidities, require specialized tranquilizer formulations. This demographic shift is likely to stimulate demand within the Tranquilizer Drugs Market, as healthcare providers seek effective solutions for managing anxiety and related disorders in older patients. ### Advancements in Pharmaceutical Research Innovations in pharmaceutical research are significantly influencing the Tranquilizer Drugs Market. The development of novel drug formulations, including extended-release and combination therapies, is enhancing the efficacy and safety profiles of tranquilizers. For instance, recent advancements have led to the introduction of drugs that target specific neurotransmitter systems, potentially reducing side effects associated with traditional tranquilizers. This evolution in drug development not only meets the needs of patients but also aligns with regulatory expectations for improved therapeutic outcomes. Consequently, the Tranquilizer Drugs Market is poised for growth as these advancements attract both healthcare providers and patients seeking more effective treatment options. ### Increasing Prevalence of Anxiety Disorders The rising incidence of anxiety disorders is a pivotal driver for the Tranquilizer Drugs Market. Recent studies indicate that approximately 18% of adults in various regions experience anxiety disorders, leading to a heightened demand for effective treatment options. This trend is likely to propel the market as healthcare providers increasingly prescribe tranquilizers to manage symptoms. Furthermore, the growing recognition of mental health issues has prompted healthcare systems to prioritize mental health care, thereby expanding the market for tranquilizers. As awareness continues to grow, the Tranquilizer Drugs Market is expected to witness substantial growth, driven by both the need for effective therapies and the increasing acceptance of mental health treatment. ### Regulatory Support for Mental Health Treatments The evolving regulatory landscape is fostering growth in the Tranquilizer Drugs Market. Governments and regulatory bodies are increasingly recognizing the importance of mental health treatments, leading to streamlined approval processes for new tranquilizer formulations. This supportive environment encourages pharmaceutical companies to invest in research and development, resulting in a wider array of tranquilizer options for patients. Additionally, regulatory initiatives aimed at promoting mental health awareness and treatment accessibility are likely to enhance market growth. As regulations become more favorable, the Tranquilizer Drugs Market is expected to expand, driven by the introduction of innovative products and increased patient access to necessary treatments. ### Increased Accessibility to Mental Health Services The expansion of mental health services is a crucial driver for the Tranquilizer Drugs Market. With the integration of mental health care into primary healthcare systems, access to treatment has improved significantly. Telehealth services and community-based programs are making it easier for individuals to seek help for anxiety and related disorders. This increased accessibility is likely to result in higher prescription rates for tranquilizers, as more patients are diagnosed and treated. Furthermore, initiatives aimed at reducing stigma surrounding mental health are encouraging individuals to pursue treatment, thereby further propelling the Tranquilizer Drugs Market. As mental health services continue to evolve, the demand for tranquilizers is expected to rise correspondingly. ## Future Outlook The Tranquilizer Drugs Market is projected to grow at a 3.6% CAGR from 2025 to 2035, driven by increasing mental health awareness and demand for anxiety treatments. **New opportunities:** - Development of personalized tranquilizer formulations Expansion into [telehealth](https://www.marketresearchfuture.com/reports/telehealth-market-900)platforms for prescription services Investment in AI-driven drug discovery for new tranquilizers By 2035, the market is expected to be robust, reflecting evolving consumer needs and innovative solutions. ## Segment Insights ### By Major Tranquilizers: Phenothiazine Derivatives (Largest) vs. Butyrophenones (Fastest-Growing) The tranquilizer drugs market is led by phenothiazine derivatives, which hold the largest share among the major tranquilizers segment. These compounds are extensively utilized due to their established efficacy in treating various psychiatric disorders. Following closely are butyrophenones, which, while not as dominant, show promising growth trends as they gain acceptance in the clinical landscape. Thioxanthene derivatives and other types occupy smaller niches, collectively contributing to a diversified portfolio of tranquilizing agents. Phenothiazine Derivatives (Dominant) vs. Butyrophenones (Emerging) Phenothiazine derivatives are regarded as the dominant class in the tranquilizer drugs market, known for their broad application and established efficacy in treating schizophrenia and other mental illnesses. Meanwhile, butyrophenones are emerging rapidly due to their potent antipsychotic properties and favorable side-effect profile, particularly in acute settings. The ongoing research into their formulations enhances their potential, positioning them as a preferred choice among healthcare providers. With growing awareness and acceptance, both segments cater to a wide range of therapeutic needs, maintaining a competitive edge in the evolving market. ### By Minor Tranquilizers: Benzodiazepine Derivatives (Largest) vs. Propanediol Dicarbamate Derivatives (Fastest-Growing) The Tranquilizer Drugs Market is notable for its diverse range of minor tranquilizers, predominantly driven by the popularity of Benzodiazepine Derivatives, which constitute the largest share in this segment. Their extensive therapeutic applications, particularly in anxiety management, contribute to their significant market presence. In contrast, Propanediol Dicarbamate Derivatives are gaining traction owing to their emerging role in treating anxiety and sleep disorders, making them a worthy competitor as they carve out a growing niche in the market. Benzodiazepine Derivatives (Dominant) vs. Propanediol Dicarbamate Derivatives (Emerging) Benzodiazepine Derivatives are the dominant force in the minor tranquilizers segment, favored for their rapid onset of action and effectiveness in treating anxiety, panic disorders, and insomnia. Their wide-ranging prescriptions underscore their established market position. Conversely, Propanediol Dicarbamate Derivatives are on an upward trajectory, noted for their unique mechanism which addresses both anxiety and sleep disturbances, appealing to healthcare providers seeking alternatives to traditional benzodiazepines. This category is characterized by ongoing research and development aiming to enhance efficacy and reduce dependency risks, establishing its growing relevance in the modern pharmaceutical landscape. ## Regional Market Share Analysis ### North America : Market Leader in Tranquilizers North America is the largest market for tranquilizer drugs, accounting for approximately 45% of the global market share. The region's growth is driven by increasing mental health awareness, a rise in anxiety disorders, and favorable regulatory frameworks that support drug approvals. The demand for innovative treatments and the presence of major pharmaceutical companies further catalyze market expansion. The United States is the leading country in this region, with significant contributions from Canada. Key players such as Pfizer, Eli Lilly, and Bristol-Myers Squibb dominate the landscape, focusing on research and development to introduce new formulations. The competitive environment is characterized by strategic partnerships and mergers aimed at enhancing product offerings and market reach. ### Europe : Regulatory Frameworks Boost Growth Europe is the second-largest market for tranquilizer drugs, holding around 30% of the global market share. The region benefits from stringent regulatory frameworks that ensure drug safety and efficacy, which in turn fosters consumer trust and demand. Increasing incidences of mental health issues and a growing elderly population are significant drivers of market growth. Leading countries in Europe include Germany, France, and the UK, where major pharmaceutical companies like Roche and Sanofi are actively involved. The competitive landscape is marked by innovation and a focus on personalized medicine. The European Medicines Agency plays a crucial role in regulating and approving new tranquilizer drugs, ensuring they meet high safety standards. "The European market is committed to enhancing mental health treatment options through rigorous regulatory processes," states the EMA. ### Asia-Pacific : Rapid Growth and Demand Asia-Pacific is witnessing rapid growth in the tranquilizer drugs market, accounting for approximately 20% of the global share. The region's expansion is fueled by increasing awareness of mental health issues, rising disposable incomes, and a growing population. Regulatory bodies are also becoming more supportive of new drug approvals, which is expected to further boost market growth. Countries like China, Japan, and India are leading the charge, with a significant presence of both local and international pharmaceutical companies. The competitive landscape is evolving, with companies focusing on affordable and effective treatment options. Key players such as Teva Pharmaceutical Industries and Mylan are actively investing in research to cater to the unique needs of the region's diverse population. ### Middle East and Africa : Emerging Market Potential The Middle East and Africa (MEA) region is emerging as a potential market for tranquilizer drugs, holding about 5% of the global market share. The growth is driven by increasing healthcare investments, rising awareness of mental health issues, and a demand for better healthcare services. Regulatory improvements are also paving the way for new drug approvals, which is crucial for market expansion. Countries like South Africa and the UAE are at the forefront of this growth, with a mix of local and international players entering the market. The competitive landscape is characterized by partnerships and collaborations aimed at enhancing product availability. Companies are focusing on addressing the unique challenges of the region, including access to healthcare and affordability of treatments. ## Competitive Benchmarking Leading market players are putting a lot of money on R&D to broaden the range of their goods, which will help the market for tranquillizer drugs grow even more. Additionally, market participants are engaging in a range of strategic initiatives to increase their worldwide reach, with important market developments such as the introduction of new products, contracts, mergers and acquisitions, increased investments, and cooperation with other organizations. To grow and endure in an increasingly competitive and challenging market environment, Tranquilizer Drugs industry must provide reasonably priced goods. One of the main business strategies employed by manufacturers is to produce locally to reduce operational expenses in the  Tranquilizer Drugs industry to develop market sector and provide benefits to customers. In recent years, the Tranquilizer Drugs industry has provided the medical business with some of the most significant benefits. Major players in the Tranquilizer Drugs Market, including AstraZeneca Plc., Eli Lilly and Company, GlaxoSmithKline plc, Merck & Co., Inc., Pfizer, Inc., Johnson & Johnson, and others, invest in operations for research and development in an effort to improve market demand. Anglo-Swedish multinational pharmaceutical and biotechnology firm AstraZeneca plc is headquartered in Cambridge, England at the Cambridge Biomedical Campus. Its product line includes treatments for serious illnesses in the cancer, cardiovascular, gastrointestinal, infectious, neurological, respiratory, and inflammatory fields. The majority of its R&D operations are based in Cambridge, England, Gothenburg, Sweden, and Gaithersburg, Maryland, in the United States. In 2021, Following the EMA's earlier clearance, the Swedish Medicines Agency, Läkemedelsverket, said that it would alter the vaccine's name to Vaxzevria, emphasizing that the vaccine's composition would remain the same. Eli Lilly and Company is an American pharmaceutical corporation with its main headquarters in Indianapolis, Indiana. About 125 nations sell its products. Colonel Eli Lilly, a pharmaceutical chemist and American Civil War veteran, started the business in 1876 and was the person who gave it its name. Merthiolate and penicillin production at Lilly reached a new peak during World War II. By the end of the war, Lilly had dried over two million pints of blood, or "about 20% of the total United States," working with the American Red Cross to process blood plasma during the conflict. In 2020, Lilly declared that its concoction was successful and that it has applied for an emergency use authorization (EUA) with the Food and Drug Administration. On the same day, Regeneron, a competitor, submitted a request for an EUA for a monoclonal antibody therapy. ## Recent News & Developments **January 2021:** The Oxford-AstraZeneca vaccine has been given the go-ahead in India, the second-most populated nation on earth, opening the door for a widespread vaccination drive. The Serum Institute of India (SII), under the trade name COVISHIELD, was announced as the local manufacturer of the Oxford-AstraZeneca shot. **June 2021: **Bentracimab's European license from PhaseBio has been approved, according to Alfasigma. In earlier clinical trials, it was discovered that the new human monoclonal antibody fragment bentracimab could counteract Brilique's and Brilinta's antiplatelet effects. **May 2021**: Lilly's request for Tyvyt (sintilimab), in addition to Lilly's own Alimta (pemetrexed) and platinum chemotherapy, for newly discovered nonsquamous non-small cell lung cancer was approved by the FDA. ## Report Scope | MARKET SIZE 2024 | 2.259(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 2.34(USD Billion) | | MARKET SIZE 2035 | 3.333(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 3.6% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Pfizer (US), Bristol-Myers Squibb (US), Roche (CH), Sanofi (FR), AstraZeneca (GB), Novartis (CH), Eli Lilly (US), Teva Pharmaceutical Industries (IL), Mylan (US) | | Segments Covered | Major Tranquilizers, Minor Tranquilizers, Region | | Key Market Opportunities | Emerging digital therapeutics and personalized medicine are reshaping the Tranquilizer Drugs Market landscape. | | Key Market Dynamics | Rising demand for mental health solutions drives innovation and competition in the tranquilizer drugs market. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the current valuation of the Tranquilizer Drugs Market as of 2024?** A: The Tranquilizer Drugs Market was valued at 2.259 USD Billion in 2024. **Q: What is the projected market valuation for the Tranquilizer Drugs Market in 2035?** A: The market is projected to reach a valuation of 3.333 USD Billion by 2035. **Q: What is the expected CAGR for the Tranquilizer Drugs Market during the forecast period 2025 - 2035?** A: The expected CAGR for the Tranquilizer Drugs Market during 2025 - 2035 is 3.6%. **Q: Which companies are considered key players in the Tranquilizer Drugs Market?** A: Key players in the market include Pfizer, Bristol-Myers Squibb, Roche, Sanofi, AstraZeneca, Novartis, Eli Lilly, Teva Pharmaceutical Industries, and Mylan. **Q: What are the major segments of the Tranquilizer Drugs Market?** A: The major segments include Phenothiazine Derivatives, Butyrophenones, Thioxanthene Derivatives, and others. **Q: What was the market size for Phenothiazine Derivatives in 2024?** A: The market size for Phenothiazine Derivatives was 0.905 USD Billion in 2024. **Q: What is the projected market size for Butyrophenones by 2035?** A: The projected market size for Butyrophenones is expected to reach 1.025 USD Billion by 2035. **Q: What are the minor tranquilizer segments in the market?** A: Minor tranquilizer segments include Benzodiazepine Derivatives, Propanediol Dicarbamate Derivatives, Cyclopyrrolone Derivatives, and others. **Q: What was the market size for Benzodiazepine Derivatives in 2024?** A: The market size for Benzodiazepine Derivatives was 0.905 USD Billion in 2024. **Q: What is the expected growth trend for the Tranquilizer Drugs Market in the coming years?** A: The Tranquilizer Drugs Market is likely to experience steady growth, with a projected valuation increase to 3.333 USD Billion by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/tranquilizer-drugs-market-21718*